Therapies that target mutant KRAS or PIK3CA proteins could also be investigated as prophylactic therapies in individuals with Noonan and Cowden syndromes, who have high cancer risk because they carry germline mutations in these genes. The gene discussed is PIK3CA; the disease is cancer.